OBJECTIVE: This study was conducted to determine whether the perioperative administration of octreotide decreases the incidence of pancreatic anastomotic leak after pancreaticoduodenectomy for malignancy. SUMMARY BACKGROUND DATA: Three multicenter, prospective, randomized trials concluded that patients who receive octreotide during and after pancreatic resection have a reduction in the total number of complications or a decreased incidence of pancreatic fistula. However, in the subset of patients who underwent pancreaticoduodenectomy for malignancy, either no analysis was performed or no benefit from octreotide could be demonstrated. METHODS: A single-institution, prospective, randomized trial was conducted between June 1991 and December 1995 involving 120 patients who were randomized to receive octreotide (150 microg subcutaneously every 8 hours through postoperative day 5) or no further treatment after pancreaticoduodenectomy for malignancy. The surgical technique was standardized, and the pancreaticojejunal anastomosis was created using the duct-to-mucosa or invagination technique. RESULTS: The two patient groups were similar with respect to patient demographics, treatment variables, and histologic diagnoses. The rate of clinically significant pancreatic leak was 12% in the octreotide group and 6% in the control group (p = 0.23). Perioperative morbidity was 30% and 25%, respectively. Patients who underwent reoperative pancreaticoduodenectomy had an increased incidence of pancreatic anastomotic leak, whereas those who received preoperative chemoradiation had a decreased incidence of pancreatic anastomotic leak. CONCLUSIONS: The routine use of octreotide after pancreaticoduodenectomy for malignancy cannot be recommended.
RCT Entities:
OBJECTIVE: This study was conducted to determine whether the perioperative administration of octreotide decreases the incidence of pancreatic anastomotic leak after pancreaticoduodenectomy for malignancy. SUMMARY BACKGROUND DATA: Three multicenter, prospective, randomized trials concluded that patients who receive octreotide during and after pancreatic resection have a reduction in the total number of complications or a decreased incidence of pancreatic fistula. However, in the subset of patients who underwent pancreaticoduodenectomy for malignancy, either no analysis was performed or no benefit from octreotide could be demonstrated. METHODS: A single-institution, prospective, randomized trial was conducted between June 1991 and December 1995 involving 120 patients who were randomized to receive octreotide (150 microg subcutaneously every 8 hours through postoperative day 5) or no further treatment after pancreaticoduodenectomy for malignancy. The surgical technique was standardized, and the pancreaticojejunal anastomosis was created using the duct-to-mucosa or invagination technique. RESULTS: The two patient groups were similar with respect to patient demographics, treatment variables, and histologic diagnoses. The rate of clinically significant pancreatic leak was 12% in the octreotide group and 6% in the control group (p = 0.23). Perioperative morbidity was 30% and 25%, respectively. Patients who underwent reoperative pancreaticoduodenectomy had an increased incidence of pancreatic anastomotic leak, whereas those who received preoperative chemoradiation had a decreased incidence of pancreatic anastomotic leak. CONCLUSIONS: The routine use of octreotide after pancreaticoduodenectomy for malignancy cannot be recommended.
Authors: M Montorsi; M Zago; F Mosca; L Capussotti; E Zotti; G Ribotta; G Fegiz; S Fissi; G Roviaro; A Peracchia Journal: Surgery Date: 1995-01 Impact factor: 3.982
Authors: G M Fuhrman; C Charnsangavej; J L Abbruzzese; K R Cleary; R G Martin; C J Fenoglio; D B Evans Journal: Am J Surg Date: 1994-01 Impact factor: 2.565
Authors: Margaret A Tempero; J Pablo Arnoletti; Stephen Behrman; Edgar Ben-Josef; Al B Benson; Jordan D Berlin; John L Cameron; Ephraim S Casper; Steven J Cohen; Michelle Duff; Joshua D I Ellenhorn; William G Hawkins; John P Hoffman; Boris W Kuvshinoff; Mokenge P Malafa; Peter Muscarella; Eric K Nakakura; Aaron R Sasson; Sarah P Thayer; Douglas S Tyler; Robert S Warren; Samuel Whiting; Christopher Willett; Robert A Wolff Journal: J Natl Compr Canc Netw Date: 2010-09 Impact factor: 11.908
Authors: Ronnie T P Poon; Sheung Tat Fan; Chung Mau Lo; Kelvin K Ng; Wai Key Yuen; Chun Yeung; John Wong Journal: Ann Surg Date: 2007-09 Impact factor: 12.969
Authors: Marco Pericoli Ridolfini; Sergio Alfieri; Stavros Gourgiotis; Dario Di Miceli; Fabio Rotondi; Giuseppe Quero; Roberta Manghi; Giovanni Battista Doglietto Journal: World J Gastroenterol Date: 2007-10-14 Impact factor: 5.742